Ginkgo Bioworks Holdings, Inc. (DNA)
After hours:
| Previous close | 2.9600 |
| Open | 3.0000 |
| Bid | 3.1800 x 29200 |
| Ask | 3.2200 x 21500 |
| Day's range | 2.9600 - 3.2250 |
| 52-week range | 2.0900 - 15.8640 |
| Volume | |
| Avg. volume | 21,971,730 |
| Market cap | 5.703B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.6720 |
| Earnings date | 16 May 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.43 |
- Simply Wall St.
Ginkgo Bioworks Holdings (NYSE:DNA) shareholders have endured a 73% loss from investing in the stock a year ago
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
- Business Wire
Twist Bioscience and Ginkgo Bioworks Sign New Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON, April 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement in
- Business Wire
Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics
BRISBANE, Australia & BOSTON, April 04, 2022--Microba Life Sciences (ASX: MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (LBP) candidates against autoimmune diseases. The collaboration aims to build on Microba’s precision approach to LBP development with an in-depth evaluation of the company’s strains using Ginkgo's high throughput,
